BLCM - priced at $7.50 | BLCM Message Board Posts


Bellicum Pharmaceuticals, Inc.

  BLCM website

BLCM   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  126 of 133  at  4/17/2018 6:28:02 PM  by

CHM_760


BLCM - priced at $7.50

HOUSTON, April 17, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $7.50 per share. The aggregate offering size, before deducting the underwriting discounts and commissions and other offering expenses, is expected to be approximately $60.0 million. The offering is expected to close on or about April 20, 2018, subject to customary closing conditions. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,200,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Citigroup and Jefferies are acting as lead book-running managers for the offering. Guggenheim Securities, Ladenburg Thalmann and Raymond James are acting as co-managers.

The securities described above are being offered by Bellicum pursuant to a shelf registration statement filed by Bellicum with the Securities and Exchange Commission (SEC), which was declared effective on July 12, 2017. A preliminary prospectus supplement related to the offering was filed with the SEC and is available for free on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to this offering, when available, may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by e-mail at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 3  
   Views: 815 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...